TytoCare
Definition
TytoCare is an Israeli company founded in 2012 that makes a home examination kit with a camera, a stethoscope and a thermometer, and adds an AI layer on top of them to detect findings.
The solution: a home exam kit, not just a video call
Telemedicine always gets stuck at the same point: you can see and hear the patient, but you cannot examine them. TytoCare, founded in 2012 by Dedi Gilad and Ofer Tzadik, solved this from the hardware side. Its home kit includes a camera for the throat and skin, an ear attachment for examining the eardrum, a digital stethoscope and a thermometer. The parent or patient uses it following on-screen guidance, and the findings are sent to the doctor in real time or for later viewing. Healthy.io took a different approach and turned the smartphone itself into an examination tool: in July 2022 it announced that Minuteful Kidney, its home kidney test, was the first smartphone-based home kidney test to receive FDA clearance.
The AI layer: what ten FDA clearances cover
The second layer is the artificial intelligence that analyzes the recordings. According to the FDA's public regulatory database, the Tyto Insights product line received ten marketing clearances between 2016 and 2026. They include 510(k) clearances for automatic detection of abnormal lung sounds: wheezes (December 2023), crackles (July 2024) and rhonchi (April 2025), as well as a De Novo authorization in March 2026 for detecting a bulging eardrum, a finding used in assessing ear infections.
What the clearances say, and what they don't
These clearances refer to flagging a finding for a professional's attention. The software does not diagnose pneumonia or an ear infection, and does not authorize treatment; the doctor decides. It is an aid inside a medical visit, not a replacement for one. This is an important regulatory distinction that comes up with every medical AI company in this category.
On the business side: funding and cutbacks
The company has raised about $205 million in total, including $49 million in 2023, and its kits are deployed in health systems in the United States, Europe and Israel. As of 2026 the company is in a period of cost cutting: in July 2025 it cut about a fifth of its workforce, and the founder-CEO moved to the role of chairman.
Why it stands out in pediatrics
A parent whose child wakes up with a fever and an earache usually has to go to a clinic in person so a doctor can look at the eardrum. A home kit that lets the doctor see and hear for themselves replaces a whole visit. That is why health systems and insurers are the main customers: not the parent, but whoever pays for the visit that was saved. Here too, the quality of the measurement depends to a large extent on who operates the device at home, a variable that is hard to control.
FAQ ❓
How many FDA clearances does TytoCare have?
Ten clearances between 2016 and 2026, according to the FDA's public regulatory database. Most are 510(k) clearances for detecting abnormal lung sounds, plus one De Novo authorization from 2026 for a bulging eardrum.
Does TytoCare's AI layer diagnose diseases?
No. The regulatory clearances define it as a tool that flags a finding for a doctor's attention. The software does not diagnose pneumonia or an ear infection, and does not authorize treatment; the clinical decision stays with the doctor.
Who are TytoCare's main customers: parents or health systems?
Mainly health systems and insurers, not the individual parent directly. The kit saves a physical clinic visit, and whoever pays for the saved visit is usually an insurer or a health system, not the family itself.
What is TytoCare's business situation as of 2026?
The company is in a period of cost cutting: in July 2025 it cut about a fifth of its workforce, and the founder-CEO moved to the role of chairman. Its total funding stands at about $205 million, and its kits are deployed in the United States, Europe and Israel.
Found a mistake, or have a source we should add? Write to us